(INBX) Inhibrx Biosciences - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.307m USD | Total Return: 537.2% in 12m
Avg Turnover: 34.5M
Qual. Beats: 0
Rev. Trend: 9.7%
Warnings
Interest Coverage Ratio -9.2 is critical
Beneish M-Score 0.12 > -1.5 - likely earnings manipulation
Altman Z'' -3.66 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Rs Leader, Idiosyncratic Leader
Inhibrx Biosciences, Inc. (INBX) is a clinical-stage biopharmaceutical firm headquartered in La Jolla, California, specializing in engineered biologic therapeutics. The company utilizes single-domain antibody (sdAb) platforms to develop multi-specific candidates designed to target complex biological pathways in oncology.
The companys pipeline features INBRX-109, a tetravalent agent targeting death-receptor 5 for chondrosarcoma, and INBRX-106, a hexavalent candidate targeting the OX40 receptor for various solid tumors. Clinical-stage biotechnology firms typically operate with high research and development expenses and rely on successful Phase 2 and 3 trial outcomes to achieve regulatory approval and commercial viability.
Analyzing the underlying clinical data and intellectual property at ValueRay can provide deeper insights into the companys valuation. Unlike traditional pharmaceutical companies with established revenue streams, biologic startups often focus on platform technologies that allow for the simultaneous development of multiple therapeutic assets.
- INBRX-109 clinical trial results drive valuation in rare bone cancer market
- Development milestones for INBRX-106 determine progress in competitive oncology landscape
- Ongoing research and development expenses dictate cash burn and capital requirements
- FDA regulatory decisions and orphan drug designations impact path to commercialization
- Strategic partnerships and licensing agreements influence long-term liquidity and pipeline validation
| Net Income: -130.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.63 > 0.02 and ΔFCF/TA -784.8 > 1.0 |
| NWC/Revenue: 11.1k% < 20% (prev 89.9k%; Δ -78.7k% < -1%) |
| CFO/TA -0.72 > 3% & CFO -131.9m > Net Income -130.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (15.6m) vs 12m ago 0.76% < -2% |
| Gross Margin: -80.38% > 18% (prev -1.20k%; Δ 1.12k% > 0.5%) |
| Asset Turnover: 0.61% > 50% (prev 0.08%; Δ 0.53% > 0%) |
| Interest Coverage Ratio: -9.18 > 6 (EBIT TTM -119.4m / Interest Expense TTM 13.0m) |
| A: 0.79 (Total Current Assets 171.3m - Total Current Liabilities 26.5m) / Total Assets 184.0m |
| B: -1.52 (Retained Earnings -279.6m / Total Assets 184.0m) |
| C: -0.56 (EBIT TTM -119.4m / Avg Total Assets 213.3m) |
| D: -0.10 (Book Value of Equity -21.0m / Total Liabilities 205.0m) |
| Altman-Z'' = -3.66 = D |
| DSRI: 0.13 (Receivables 186k/214k, Revenue 1.30m/200k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.85 (AQ_t 0.02 / AQ_t-1 0.03) |
| SGI: 6.50 (Revenue 1.30m / 200k) |
| TATA: 0.01 (NI -130.2m - CFO -131.9m) / TA 184.0m) |
| Beneish M = 0.12 (Cap -4..+1) = D |
As of June 12, 2026, the stock is trading at USD 93.54 with a total of 358,947 shares traded.
Over the past week, the price has changed by +2.51%,
over one month by -26.68%,
over three months by +27.27% and
over the past year by +537.19%.
Inhibrx Biosciences has no consensus analysts rating.
P/S = 1005.5405
P/B = 212.2835
Revenue TTM = 1.30m USD
EBIT TTM = -119.4m USD
EBITDA TTM = -117.1m USD
Long Term Debt = 175.0m USD (from longTermDebt, last quarter)
Short Term Debt = 2.41m USD (from shortTermDebt, last quarter)
Debt = 183.3m USD (corrected: LT Debt 175.0m + ST Debt 2.41m) + Leases 5.90m
Net Debt = 21.6m USD (calculated: Debt 183.3m - CCE 161.7m)
Enterprise Value = 1.33b USD (1.31b + Debt 183.3m - CCE 161.7m)
Interest Coverage Ratio = -9.18 (Ebit TTM -119.4m / Interest Expense TTM 13.0m)
EV/FCF = -11.41x (Enterprise Value 1.33b / FCF TTM -116.5m)
FCF Yield = -8.77% (FCF TTM -116.5m / Enterprise Value 1.33b)
FCF Margin = -8.96k% (FCF TTM -116.5m / Revenue TTM 1.30m)
Net Margin = -10.0k% (Net Income TTM -130.2m / Revenue TTM 1.30m)
Gross Margin = -80.38% ((Revenue TTM 1.30m - Cost of Revenue TTM 2.35m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 7.22 (Enterprise Value 1.33b / Total Assets 184.0m)
Interest Expense / Debt = 7.10% (Interest Expense 13.0m / Debt 183.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -94.4m (EBIT -119.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.86 (Total Current Assets 171.3m / Total Current Liabilities 35.3m)
Debt / Equity = -8.71 (negative equity) (Debt 183.3m / totalStockholderEquity, last quarter -21.0m)
Debt / EBITDA = -0.18 (negative EBITDA) (Net Debt 21.6m / EBITDA -117.1m)
Debt / FCF = -0.19 (negative FCF - burning cash) (Net Debt 21.6m / FCF TTM -116.5m)
Total Stockholder Equity = 23.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -61.03% (Net Income -130.2m / Total Assets 184.0m)
RoE = -563.9% (Net Income TTM -130.2m / Total Stockholder Equity 23.1m)
RoCE = -60.30% (EBIT -119.4m / Capital Employed (Equity 23.1m + L.T.Debt 175.0m))
RoIC = -59.05% (negative operating profit) (NOPAT -94.4m / Invested Capital 159.8m)
WACC = 11.94% (E(1.31b)/V(1.49b) * Re(12.83%) + D(183.3m)/V(1.49b) * Rd(7.10%) * (1-Tc(0.21)))
Discount Rate = 12.83% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 13.80 | Cagr: -42.45%
[DCF] Fair Price = unknown (Cash Flow -116.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.02 | # QB: 0
Revenue Correlation: 9.71 | Revenue CAGR: 9.47% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.34 | Chg30d=+0.00% | Revisions=N/A | Analysts=1
EPS next Quarter (2026-09-30): EPS=-1.44 | Chg30d=+0.00% | Revisions=N/A | Analysts=1
EPS current Year (2026-12-31): EPS=-5.46 | Chg30d=+0.00% | Revisions=N/A | GrowthEPS=+39.6% | GrowthRev=-100.0%
EPS next Year (2027-12-31): EPS=-2.79 | Chg30d=+0.00% | Revisions=N/A | GrowthEPS=+48.9% | GrowthRev=+0.0%